Answers are grounded in this paper and cite their sources.
Several factors contribute to the development of hyperglycemia in type 2 diabetes mellitus, especially the increase of hepatic gluconeogenesis and the insulin secretion and sensitivity. The glucokinase activators (GKAs) act on these pathogenetic mechanisms by promoting glucose metabolism, representing a new potential class of drugs able to regulate glycemia and enhance β-cell function. This review reports the current literature about the mechanisms of action of these new-generation GKAs and assess their efficacy and safety in treating T2DM based on preclinical studies and clinical trials.
No takes yet. Share an insight, caveat, or question.
Boni et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: